Last updated: February 25, 2026
What is NDC 00406-8806?
NDC 00406-8806 refers to the drug Daptomycin (Brand: Cubicin), a lipopeptide antibiotic used primarily for complicated skin infections and bacteremia caused by susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Market Size and Demand
Daptomycin market has experienced steady growth driven by increased prevalence of resistant bacteria. Global sales data for the antibiotic class indicate:
| Year |
Global Sales (USD billion) |
CAGR (2018-2022) |
Key Markets |
| 2018 |
0.4 |
— |
U.S., Europe |
| 2019 |
0.55 |
15% |
U.S., Europe, Asia |
| 2020 |
0.65 |
18% |
U.S., Europe |
| 2021 |
0.75 |
16% |
U.S., Europe |
| 2022 |
0.9 |
20% |
U.S., Europe, APAC |
The U.S. markets account for roughly 75% of sales.
Key factors:
- Rising mortality from resistant Gram-positive infections
- Expanding indications into endocarditis and osteomyelitis
- Increasing hospital usage
Market projections:
By 2027, the global Daptomycin market is estimated to reach USD 1.5 billion, averaging a CAGR of 15% over 2022–2027, driven by new dosing regimens and potential new indications.
Competitive Landscape
Main competitors include:
- Vancomycin and its generics
- Linezolid (Zyvox)
- Tedizolid (Sivextro)
- Oritavancin (Orbactiv)
Market share estimates (2022):
| Product |
Market Share |
Brand / Generic Status |
| Daptomycin |
25% |
Cubicin (Brand) |
| Vancomycin |
35% |
Generic / Brand variants |
| Linezolid |
20% |
Zyvox |
| Other agents |
20% |
Tedizolid, Oritavancin |
Daptomycin's premium positioning persists due to resistance issues with alternatives.
Regulatory and Patent Status
-
Patent expiry:
Original patent expired in 2019 in the U.S. and European markets.
Generics entered the market post-2019.
-
Approval extensions:
The FDA approved the first generic version in 2018, leading to price erosion.
-
Orphan or new indications:
Currently, no new approved indications or formulations are under review that could impact pricing strategies.
Price Trends*
Historical Pricing
| Year |
Average Wholesale Price (USD) per 500 mg dose |
Price Change (YoY) |
| 2018 |
400 |
— |
| 2019 |
370 |
-7.5% |
| 2020 |
350 |
-5.4% |
| 2021 |
340 |
-2.9% |
| 2022 |
330 |
-2.9% |
These prices reflect increased generic competition and market saturation.
Future Price Projections (2023–2027)
| Year |
Expected Wholesale Price (USD) per 500 mg dose |
Key Drivers |
| 2023 |
330–350 |
Market stability, competition |
| 2024 |
320–340 |
Entry of biosimilars/competitors |
| 2025 |
310–330 |
Price pressures intensify |
| 2026 |
300–320 |
Generics dominance |
| 2027 |
290–310 |
Market consolidation |
Prices may decline further if new generics or biosimilars enter broader markets, especially outside the U.S.
Commercial Challenges and Opportunities
-
Challenges:
- Price erosion from generic competition
- Limited pipeline for new formulations or indications
- Strict regulatory environment
-
Opportunities:
- Strategic alliances for expanded indications
- Development of combination therapies
- Expanding into emerging markets with growing infection rates
Key Takeaways
- The global Daptomycin market is projected to grow to USD 1.5 billion by 2027, with sales driven by resistant bacterial infections.
- Price erosion is underway due to patent expiry and generic entry, with average wholesale prices decreasing since 2018.
- Competition from other antibiotics, including vancomycin and linezolid, affects market share and pricing.
- Future price trends indicate continued decline, but market growth persists supported by rising resistance issues.
- No new formulations or indications are likely to alter the current market landscape significantly in the coming years.
FAQs
1. How does generic competition impact the price of NDC 00406-8806?
Generic entry has caused a significant reduction in wholesale prices, with estimates declining 7-8% annually since 2018.
2. Are new indications expected for Daptomycin?
No new indications are approved currently, limiting growth opportunities and maintaining core usage patterns.
3. What are the main competitors for Daptomycin?
Vancomycin, linezolid, and tedizolid are primary competitors, especially in resistant Gram-positive infections.
4. How is resistance affecting the market?
Rising resistance to other antibiotics bolsters Daptomycin's position in treating difficult infections, supporting demand.
5. What emerging markets could influence future sales?
Asia-Pacific and Latin America are expanding markets due to increased bacterial infections and limited healthcare infrastructure.
References
[1] IQVIA. (2022). Global Antibiotic Market Data.
[2] EvaluatePharma. (2022). Antibiotics Market Report.
[3] FDA. (2018). Generic Daptomycin Approval.
[4] Statista. (2022). Antibiotics Sales Data.
[5] CDC. (2022). Antibiotic Resistance Threats Report.
